Real-time enrollment status for this relapsed/refractory b-cell malignancies clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 7:39 AM UTC
| NCT Number | NCT06590961 |
| Recruiting Status | Recruiting |
| Condition | Relapsed/Refractory B-cell Malignancies |
| Phase | Clinical Trial |
| Target Enrollment | 94 participants |
| Active Locations | 3 sites in the US |
| Sponsor | Ubix Therapeutics, Inc. |
| Last Updated on CT.gov | November 19, 2025 (Nov 19, 2025) |
As of July 13, 2026: Clinical trial NCT06590961 is currently recruiting participants. This clinical trial study for relapsed/refractory b-cell malignancies is actively seeking new participants at 3 locations across the United States. The study is sponsored by Ubix Therapeutics, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06590961 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 3 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06590961 was last updated Nov 19, 2025 (November 19, 2025). HelloStudys verifies this status automatically.